Vendor Matrix
Biotech AI Platform Landscape
Side-by-side comparison of biotech AI platforms across genomics/protein AI, lab automation AI, data management AI, and regulatory AI by development stage.
This matrix compares AI platform categories for biotechnology companies across the dimensions that drive scientific and commercial value: modality focus, data integration, computational scale, IP protection, and closed-loop experimental capability. Over 200 million protein structures have been predicted by AlphaFold, but structure is just the beginning — function prediction is where AI-native biotechs are building competitive moats. Biotechs using AI-driven design-build-test-learn cycles report 5-10x improvement in experimental efficiency. Use this matrix alongside the AI for Biotech R&D decision guide.
Platform Comparison by Capability
| Evaluation Criteria | Genomics / Protein AI | Lab Automation AI | Data Management AI | Regulatory AI |
|---|---|---|---|---|
| Core Function | Variant analysis, protein design, multi-omics | Experiment planning, robotic workflows | LIMS integration, data pipelines | IND/BLA prep, GxP documentation |
| Primary Value | Novel target discovery, therapeutic design | Experimental throughput (5-10x) | Data quality, AI-readiness | Submission speed, compliance |
| Data Requirements | Sequencing, structural, activity data | Experimental results, protocols | All lab instrument + metadata | Clinical, manufacturing, nonclinical |
| Computational Scale | Very High (GPU clusters, large models) | Moderate | Moderate-High (ETL pipelines) | Low-Moderate |
| IP Sensitivity | Very High (designs are the product) | Low-Moderate | Moderate (data ownership) | Moderate (submission content) |
| Build vs. Buy | Hybrid — buy platform, build models | Buy (instrument-specific) | Build (core infrastructure) | Buy (specialized tooling) |
| Time to Value | 6-12 months | 2-4 months | 3-6 months | 2-4 months |
| Typical Pricing Model | Compute + platform license | Per-instrument / platform fee | Platform license + storage | Per-submission / SaaS |
Selection Criteria by Development Stage
| Factor | Pre-clinical | Clinical | Commercial |
|---|---|---|---|
| Primary AI Priority | Target discovery, molecular design | Clinical data management, regulatory prep | Manufacturing optimization, post-market |
| Data Infrastructure Maturity | Building — invest early for 10x returns | Moderate — integrating clinical systems | Extensive — multi-site, multi-system |
| Vendor Approach | AI-native partnerships, co-development | Best-of-breed per function | Enterprise platform + specialists |
| GxP Requirements | Minimal (research use only) | High (21 CFR Part 11, data integrity) | Very High (cGMP, full validation) |
| Budget Range (Annual AI) | $200K-$2M | $2M-$10M | $10M-$50M+ |
Vendor Shortlist Criteria
- Scientific validation — published results in peer-reviewed journals with experimentally confirmed AI predictions
- Data integration — connectivity to your LIMS, ELN, sequencers, and instrument data systems for closed-loop workflows
- IP ownership — clear contractual terms ensuring all designs, sequences, and experimental data remain your exclusive property
- Computational infrastructure — GPU access, scalability, and cost predictability at your current and projected data volumes
- Model interpretability — scientists must understand the biological rationale behind AI recommendations, not just predictions
- Closed-loop capability — ability to ingest experimental results and improve predictions iteratively in design-build-test-learn cycles
Key decision point
Most biotech AI failures trace to data infrastructure, not algorithms. Experimental results trapped in spreadsheets, inconsistent assay protocols across sites, and instrument data that does not flow into analysis pipelines automatically. Invest in data infrastructure before hiring your first ML scientist. Biotechs that build the pipeline first get 10x more value from every AI dollar spent.